Figure 6.

HSV1716 Treatment Increases CD8⁺ T Cell Infiltration and Lowers Incidence of Regulatory T Cells

Mice bearing 76-9 tumors were treated as previously described and sacrificed 3 days after the final dose of HSV1716 or PBS control. Single-cell suspensions were obtained from isolated tumors, stained, and then analyzed via flow cytometry. (A) Total T cell infiltrates presented as a percentage of total living cells. (B) Percentage of CD4⁺ T cells. (C) Percentage of total CD4⁺ T cells displaying a T regulatory cell phenotype (Foxp3⁺/CD25⁺). (D) Percentage of CD8⁺ T cells. (E) Percentage of CD8⁺ cells displaying a memory T cell phenotype (CD44⁺). (F) Percentage of CD8⁺ T cells specific for HSV1716 glycoprotein B (GB). (G) The ratio of CD8⁺ T cells to T regulatory cells. n = 4 tumors were analyzed for each group, with the exception of A8301+HSV1716, which had n = 7. Statistical significance was determined with one-way ANOVA (*p = 0.05–0.005; **p = 0.005–0.0005; ***p < 0.0005). Error bars represent SD.